The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study.
Effectiveness
Golimumab
Health-related quality of life
Patient-reported outcomes
Real-world study
Rheumatoid arthritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
14
11
2021
accepted:
15
12
2021
pubmed:
30
1
2022
medline:
19
4
2022
entrez:
29
1
2022
Statut:
ppublish
Résumé
This study aimed at assessing the impact of golimumab on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) in real-world settings. GO-Q was an observational, prospective, 12-month study, which recruited patients with moderate-to-severely active RA initiating golimumab treatment per label in rheumatology clinics and private practices. Primary endpoint was the change in PROs [EuroQol-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire, Health Assessment Questionnaire Disease Index (HAQ-DI), and Work Productivity and Activity Index for RA (WPAI:RA)] after 12 months of treatment. Other endpoints included Disease Activity Score for 28 joints with erythrocyte sedimentation rate (DAS28-ESR), healthcare resource utilization, and golimumab adherence. Changes in continuous variables from baseline were evaluated with the paired t test. One hundred forty-five patients were recruited. The mean [standard deviation (SD)] EQ-5D-3L index increased significantly at 12 months versus baseline [from 0.427 (0.206) to 0.801 (0.229); p < 0.0001], with changes as early as 3 and 6 months (both p < 0.0001). Accordingly, there were statistically significant changes in all WPAI:RA domains from baseline to 3, 6, and 12 months (p < 0.0001). Patients' function improved gradually from the third month until the end of follow-up (p < 0.0001 for all time-points). Thirty (27.3%) and 60 (54.6%) patients achieved remission (DAS28-ESR < 2.6) and low disease activity (DAS28-ESR ≤ 3.2), respectively, at 12 months. Adherence rate to golimumab was high (mean [SD] 90.3% (7.5) at 12 months). In patients with moderate-to-severely active RA, golimumab significantly improved HRQoL, physical function, and work productivity and activity, with improvements in disease activity over 12 months in real-world settings.
Identifiants
pubmed: 35091757
doi: 10.1007/s00296-021-05073-1
pii: 10.1007/s00296-021-05073-1
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antirheumatic Agents
0
golimumab
91X1KLU43E
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
639-650Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
doi: 10.1016/S0140-6736(16)30173-8
pubmed: 27156434
pmcid: 27156434
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637. https://doi.org/10.1136/ard.2009.123919
doi: 10.1136/ard.2009.123919
pubmed: 20215140
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655
doi: 10.1136/annrheumdis-2019-216655
pubmed: 31969328
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 67(10):1360–1364. https://doi.org/10.1136/ard.2008.091454
doi: 10.1136/ard.2008.091454
pubmed: 18791055
Gossec L, Dougados M, Dixon W (2015) Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 1(1):e000019. https://doi.org/10.1136/rmdopen-2014-000019
doi: 10.1136/rmdopen-2014-000019
pubmed: 26509052
pmcid: 4613162
Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T et al (2018) Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int 38(6):935–947. https://doi.org/10.1007/s00296-018-4005-5
doi: 10.1007/s00296-018-4005-5
pubmed: 29564549
pmcid: 5953992
Senolt L (2019) Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res. https://doi.org/10.12688/f1000research.18688.1
doi: 10.12688/f1000research.18688.1
pubmed: 31508202
pmcid: 6719675
Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K, BSRBR-RA Contributors Group (2019) Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford) 58:2162–2169. https://doi.org/10.1093/rheumatology/kez188
doi: 10.1093/rheumatology/kez188
Chatzidionysiou K (2020) Beyond methotrexate and biologics in RA—efficacy of JAK inhibitors and their place in the current treatment armamentarium. Mediterr J Rheumatol 31(1):120–128. https://doi.org/10.31138/mjr.31.1.120
doi: 10.31138/mjr.31.1.120
pubmed: 32676570
pmcid: 7361190
Genitsaridi I, Flouri I, Plexousakis D, Marias K, Boki K, Skopouli F et al (2020) Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Arthritis Res Ther 22(1):226. https://doi.org/10.1186/s13075-020-02313-w
doi: 10.1186/s13075-020-02313-w
pubmed: 32993800
pmcid: 7523072
Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36(5):685–695. https://doi.org/10.1007/s00296-015-3415-x
doi: 10.1007/s00296-015-3415-x
pubmed: 26746843
pmcid: 4839053
Strand V, Singh JA (2010) Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 70(2):121–145. https://doi.org/10.2165/11531980-000000000-00000
doi: 10.2165/11531980-000000000-00000
pubmed: 20108988
El Miedany Y, El Gaafary M, El Arousy N, Ahmed I, Youssef S, Palmer D (2012) Arthritis education: the integration of patient-reported outcome measures and patient self-management. Clin Exp Rheumatol 30(6):899–904
pubmed: 22992291
Uhlig T, Loge JH, Kristiansen IS, Kvien TK (2007) Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 34(6):1241–1247
pubmed: 17516624
Pincus T, Sokka T (2003) Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 17(5):753–781
doi: 10.1016/S1521-6942(03)00077-9
European Medicines Agency. Simponi. https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf . Accessed 11 Dec 2020
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272–2283. https://doi.org/10.1002/art.24638
doi: 10.1002/art.24638
pubmed: 19644849
Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC et al (2009) Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789–796. https://doi.org/10.1136/ard.2008.099010
doi: 10.1136/ard.2008.099010
pubmed: 19066176
Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicenandomizedmised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210–221. https://doi.org/10.1016/S0140-6736(09)60506-7
doi: 10.1016/S0140-6736(09)60506-7
pubmed: 19560810
Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T et al (2012) Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 39(6):1185–1191. https://doi.org/10.3899/jrheum.111195
doi: 10.3899/jrheum.111195
pubmed: 22505702
Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C et al (2019) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int 39(3):509–515. https://doi.org/10.1007/s00296-018-4177-z
doi: 10.1007/s00296-018-4177-z
pubmed: 30353269
Pombo M, Sánchez-Piedra C, Cea-Calvo L et al (2020) FRI0290 factors associated with persistence of golimumab treatment in the BIOBADASER registry, up to 7 years of follow-up. Ann Rheum Dis 79:733–734
doi: 10.1136/annrheumdis-2020-eular.3490
Dejaco C, Mueller T, Zamani O, Kurtz U, Egger S, Resch-Passini J et al (2018) Golimumab improves work productivity and activity as well as quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PsA) and axial spondyloarthritis (axSpA): interim results from a non-interventional study in Austria (go active) [abstract]. In2018 ACR/ARHP Annual Meeting 2018, Arthritis Rheumatol, 70 (suppl 10)
Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH (2019) Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int 39(1):131–140. https://doi.org/10.1007/s00296-018-4180-4
doi: 10.1007/s00296-018-4180-4
pubmed: 30415451
Iannone F, Favalli EG, Caporali R, D’Angelo S, Cantatore FP, Sarzi-Puttini P et al (2021) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88(1):105062. https://doi.org/10.1016/j.jbspin.2020.07.011
doi: 10.1016/j.jbspin.2020.07.011
pubmed: 32755721
Krueger K, Remstedt S, Thiele A, Hohenberger S (2020) Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. J Comp Eff Res 9(12):891–902. https://doi.org/10.2217/cer-2020-0092
doi: 10.2217/cer-2020-0092
pubmed: 32722921
Mourão AF, Ribeiro C, Borges J, Gonçalves MJ, Bernardes M, Fernandes S et al (2017) Real-life effectiveness of Golimumab in biologic-naïve patients with rheumatoid arthr–tis—data from the rheumatic diseases portuguese register (Reuma.pt). Acta Reumatol Port 42:141–149
pubmed: 28371797
Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH (2018) Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 8(6):e021082. https://doi.org/10.1136/bmjopen-2017-021082
doi: 10.1136/bmjopen-2017-021082
pubmed: 29903793
pmcid: 6009562
Krüger K, Burmester GR, Wassenberg S, Thomas MH (2020) Golimumab as the first, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany. Rheumatol Ther 7(2):371–382. https://doi.org/10.1007/s40744-020-00204-9
doi: 10.1007/s40744-020-00204-9
pubmed: 32303994
pmcid: 7211218
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324. https://doi.org/10.1002/art.1780310302
doi: 10.1002/art.1780310302
pubmed: 3358796
Fransen J, van Riel PL (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93-99. https://doi.org/10.1016/j.rdc.2009.10.001
doi: 10.1016/j.rdc.2009.10.001
pubmed: 16273792
EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9
doi: 10.1016/0168-8510(90)90421-9
Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53–72. https://doi.org/10.1016/0168-8510(96)00822-6
doi: 10.1016/0168-8510(96)00822-6
pubmed: 10158943
EuroQol Group. EQ-5D-3L User Guide. https://euroqol.org/publications/user-guides/ Accessed 09 Nov 2021
Bruce B, Fries JF (2005) The health assessment questionnaire (HAQ). Clin Exp Rheumatol 23(39):S14-18
pubmed: 16273780
Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353–365. https://doi.org/10.2165/00019053-199304050-00006
doi: 10.2165/00019053-199304050-00006
pubmed: 10146874
Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48. https://doi.org/10.1002/art.1780380107
doi: 10.1002/art.1780380107
pubmed: 7818570
Wen H, Ralph Schumacher H, Li X, Gu J, Ma L, Wei H et al (2012) Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international study. Int J Rheum Dis 15(4):380–389. https://doi.org/10.1111/j.1756-185X.2012.01752.x
doi: 10.1111/j.1756-185X.2012.01752.x
pubmed: 22898218
Nemoto T, Ito S, Kobayashi D, Takai C, Sakai S, Kurosawa Y et al (2021) Long-term use of golimumab in daily practice for patients with rheumatoid arthritis. Intern Med 60(9):1359–1367. https://doi.org/10.2169/internalmedicine.5381-20 (Erratum in: Intern Med. 2021;60(13):2163)
doi: 10.2169/internalmedicine.5381-20
pubmed: 33250460
Akar S, Kalyoncu U, Dalkilic E, Emmungil H, Aziz A, Esen Y, Koc T (2021) GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. Immunotherapy 13(10):841–850. https://doi.org/10.2217/imt-2020-0296
doi: 10.2217/imt-2020-0296
pubmed: 33955239
Nieto JC, Arajol C, Carmona L, Marras C, Cea-Calvo L (2021) Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy 13(5):433–458. https://doi.org/10.2217/imt-2021-0011
doi: 10.2217/imt-2021-0011
pubmed: 33557600
Calvo-Alén J, Monteagudo I, Salvador G, Vázquez-Rodríguez TR, Tovar-Beltrán JV, Vela P, Maceiras F et al (2017) Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol 35(3):423–430
pubmed: 28032846
Stolshek BS, Wade S, Mutebi A, De AP, Wade RL, Yeaw J (2018) Two-year adherence and costs for biologic therapy for rheumatoid arthritis. Am J Manag Care 24:SP315–SP321
pubmed: 30020744
Sato E, Tanaka E, Ochiai M, Shimizu Y, Kobayashi A, Shidara K et al (2015) Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Mod Rheumatol 25(3):350–357. https://doi.org/10.3109/14397595.2014.958274
doi: 10.3109/14397595.2014.958274
pubmed: 25619283
Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: clinical applications. Dis Markers 35(6):727–734. https://doi.org/10.1155/2013/726598
doi: 10.1155/2013/726598
pubmed: 24324289
pmcid: 3845430
Eker YÖ, Pamuk ÖN, Pamuk GE, Dönmez S, Çakır N (2014) The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: a comparative study. Eur J Rheumatol 1(2):67–71. https://doi.org/10.5152/eurjrheumatol.2014.022
doi: 10.5152/eurjrheumatol.2014.022
pubmed: 27708878
pmcid: 5042281
Nikiphorou E, Sjöwall C, Hannonen P, Rannio T, Sokka T (2016) Long-term outcomes of destructive seronegative (rheumatoid) arthritis—description of four clinical cases. BMC Musculoskelet Disord 3(17):246. https://doi.org/10.1186/s12891-016-1067-y
doi: 10.1186/s12891-016-1067-y
Johnston BC, Patrick DL, Devji T, Maxwell LJ, Bingham III CO, Beaton D, Boers M et al (2021) Chapter 18: Patient-reported outcomes. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane. Available from www.training.cochrane.org/handbook . Accessed 06 July 2021
Kontodimopoulos N, Pappa E, Niakas D, Yfantopoulos J, Dimitrakaki C, Tountas Y (2008) Validity of the EuroQoL (EQ-5D) instrument in a greek general population. Value In Health 11(7):1162–1169. https://doi.org/10.1111/j.1524-4733.2008.00356.x
doi: 10.1111/j.1524-4733.2008.00356.x
pubmed: 18489492